Virulence Plasmids of *Rhodococcus equi* Isolates From Cuban Patients With AIDS

Daniel Salazar-Rodríguez 1, Yamilé Aleaga-Santiesteban 1, Enrique Iglesias 2, Arturo Plascencia-Hernández 3, Héctor R. Pérez-Gómez 3, Enrique J. Calderón 4, José A. Vázquez-Boland 5 and Yaxsier de Armas 1,6*

1 Department of Clinical Microbiology Diagnostic, Hospital Center of Institute of Tropical Medicine “Pedro Kourí,” Havana, Cuba, 2 Departamento de Vacunas, Centro de Ingeniería Genética y Biotecnología, Havana, Cuba, 3 Centro Universitario de Ciencias de la Salud de la Universidad de Guadalajara, Guadalajara, Mexico, 4 Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocio/Consejo Superior de Investigaciones Científicas/Universidad de Sevilla, Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Seville, Spain, 5 Microbial Pathogenesis Group, Edinburgh Medical School (Biomedical Sciences - Infection Medicine), University of Edinburgh, Edinburgh, United Kingdom, 6 Pathology Department, Hospital Center of Institute of Tropical Medicine “Pedro Kourí,” Havana, Cuba

*Correspondence: Yaxsier de Armas yaxsier@ipk.sld.cu

**Specialty section:** This article was submitted to Parasitology, a section of the journal Frontiers in Veterinary Science

**Received:** 11 November 2020

**Accepted:** 05 January 2021

**Published:** 25 February 2021

**Citation:** Salazar-Rodríguez D, Aleaga-Santiesteban Y, Iglesias E, Plascencia-Hernández A, Pérez-Gómez HR, Calderón EJ, Vázquez-Boland JA and de Armas Y (2021) Virulence Plasmids of *Rhodococcus equi* Isolates From Cuban Patients With AIDS. Front. Vet. Sci. 8:628239, doi: 10.3389/fvets.2021.628239

**Keywords:** *Rhodococcus equi*, aids, human immunodeficiency virus, Cuba, animal host-associated virulence plasmids, TRAVAP virulence plasmid typing, *R. equi* zoonotic infection

**INTRODUCTION**

*Rhodococcus equi* is a well-known horse pathogen first described in 1923 by Magnusson as the causative agent of pyogranulomatous pneumonia and lung abscesses in foals aged <6 months (1). *R. equi* also infects other mammals including pigs, cattle, goats, cats, dogs, and humans, in which the infection is believed to be zoonotic (2). The first case of human infection was reported in an adult receiving immunosuppressive therapy in 1966. In the 1980–90’s, *R. equi* emerged as an opportunistic pathogen associated with AIDS and other immunosuppressive conditions such as organ transplant chemotherapy and steroid therapy. In humans, *R. equi* causes purulent bronchopneumonia and occasional extrapulmonary pyogenic infections (3, 4).
Rhodococcus equi in Cuba

R. equi is widespread in nature, inhabits soil and colonizes the intestine of grazing animals and omnivores. The most likely transmission mechanism is inhalation of the bacteria in aerosolized dust particles. In addition, the accidental inoculation of the microorganism in injuries, mucous membranes or ingestion of contaminated food are other possible routes of infection (5). The pathogen is a facultative intracellular parasite capable of replicating within macrophages, thus evading host defense mechanisms (2, 6, 7).

The pathogenicity of R. equi is associated with the presence of a virulence plasmid encoding a family of “Virulence Associated Proteins” (VAPs) (2, 6–8). Two different R. equi circular virulence plasmid variants were initially characterized: the VapA-encoding pVAPA, found in virulent isolates of equine origin, and the VapB-encoding pVAPB, found in isolates showing intermediate virulence in mice, recovered from submaxillary lymph nodes of slaughtered pigs and human clinical specimens (2, 9–11). Recently, the VapN-encoding linear virulence plasmid, pVAPN, was identified in isolates from boids and human clinical specimens (12). These R. equi virulence plasmids are animal host-specific, with pVAPA being associated with horses, pVAPB with pigs and pVAPN with cattle (ruminants) (2, 8, 11–13). Human isolates, in contrast, can carry any of the three animal host-associated plasmid types. This finding suggested that humans were accidental hosts for R. equi and that human infections had a zoonotic origin (2, 8, 13).

Molecular typing of R. equi is insufficiently developed and little is known about the epidemiology and transmission of this multihost pathogen (13). Thus far, there has only been one case report of a human R. equi infection in Cuba (14). In this study, we used the PCR-based virulence plasmid typing system developed by Ocampo-Sosa et al. (13), complemented with the novel vapN marker for the ruminant-associated virulence plasmid pVAPN (12), to analyze the virulence plasmid carriage of a series of human R. equi strains recently isolated from people living with HIV in Cuba.

The DNA extracted from each isolate (50 ng) was PCR-amplified in a reaction volume of 50 µL, using the traA-, vapA-, and vapB-specific primers of the TRAVAP typing system (13) updated with additional primers for the vapN gene marker for the novel pVAPN plasmid (12). The sequences of the primers are shown in Supplementary Table 1. PCR reactions were performed using the modifications reported elsewhere (15).

Previously, the isolates were confirmed as R. equi based on the amplification of a fragment of the choE gene encoding cholesterol oxidase (16).

For the detection of each PCR product, 15 µL of the resulting mixture was run on a 1.6% agarose gel containing ethidium bromide. The visualization of the amplicons was carried out by exposing the gel to ultraviolet light in a transilluminator equipment (Macrorvue 2011, LKB, Sweden).

The study was approved by the Ethic Committee of Institute of Tropical Medicine “Pedro Kouri” (CEI-IPK 51-18). It was conducted in accordance with national regulations and the Declaration of Helsinki. All participants signed a written informed consent.

RESULTS

The analysis of the 26 isolates of R. equi showed that 4 (15.4%) were positive for the vapA gene of the equine-associated pVAPA virulence plasmid. The porcine-associated pVAPB plasmid was identified in six isolates (23.1%), as determined by a positive reaction for the vapB gene marker. One isolate gave a positive PCR with the vapN marker, suggesting it carried the ruminant-associated pVAPN plasmid. The traA gene was detected in a total 11 of the 26 cases analyzed (42.3%). Most isolates in this investigation (53.8%) were TRAVAP negative (i.e., negative to the traA, vapA, vapB, and vapN PCR markers). The classification of the isolates according to the TRAVAP system is shown in Supplementary Table 2 and the percentage distribution of each virulence plasmid type in the analyzed sample in Supplementary Table 3.

DISCUSSION

In this study, we provide the first molecular characterization of R. equi isolates in people living with HIV/AIDS in Cuba, with a focus on the molecular analysis of the animal host-adapted virulence plasmids using the PCR-based TRAVAP typing method (13). These plasmids, designated pVAPA, pVAPB, and pVAPN (2, 11, 12), enable R. equi to, respectively, colonize horses, pigs, and ruminants, while they can at the same time be indistinctly found in isolates recovered from non-adapted animal species (i.e., the case of humans) (2, 8). Because these plasmids are associated with specific animal hosts, it is in principle possible to infer the source of zoonotic transmission of human R. equi isolates by determining the type of virulence plasmid they carry. The molecular typing of the R. equi virulence plasmids has therefore recently emerged as a tool of great epidemiological importance that can provide valuable insight into the possible sources of human rhodococcal infections (2, 12, 13).

MATERIALS AND METHODS

A case series study of 26 isolates of R. equi from 26 people living with HIV/AIDS was conducted during the period between January 2010 and December 2016. These isolates were obtained from all the patients with R. equi / HIV coinfection (one isolate/patient) admitted to the Hospital Center of Institute of Tropical Medicine “Pedro Kouri” (IPK) during this 7-year period. The isolates belong to the collection of the Department of Clinical Microbiology Diagnostic of the Hospital Center of IPK, Havana, Cuba. No data were available in the clinical records of previous contact of patients with farm animals or farm environments.

R. equi isolates were stored at −70°C and revived by incubation in Muller-Hilton broth at 37°C for 24 h. The colonies from the isolates were used for DNA purification using QIAmp kit (Qiagen, Hilden, Germany) following manufacturer’s instructions.

Declaration of Helsinki. All participants signed a written informed consent.

Supplementary Table 1

Supplementary Table 2

Supplementary Table 3
A previous survey involving a global collection of *R. equi* isolates showed that about half of human strains carried a pVAPB (porcine type) plasmid (13), suggesting that exposure to pig farms is a major risk factor. This is consistent with our finding that most of the virulence plasmid-positive Cuban isolates carried the pVAPB plasmid type. Our results are comparable to those of previous studies by Takai et al. in Thailand (10), and Ribeiro et al. in Brazil (17, 18), also involving human isolates from HIV-infected patients, which found that the most abundant plasmid type in these isolates was the porcine (vapB<sup>+</sup>) plasmid type, pVAPB. This indicates that the infection by *R. equi* in the sample of Cuban people living with HIV/AIDS involves, like in other countries, the pig as the probable main source of transmission of the microorganism. Pork is one of the main sources of protein intake by Cuban people and many individuals are in close contact with pigs for breeding and meat trade.

The first of the Vap antigen-encoding virulence plasmids to be identified, by Takai et al. in 1991, was the equine-associated pVAPA (9, 19). This plasmid is as an essential virulence determinant of the pathogen in foals and mice (20). In the present work, four human isolates carrying the pVAPA plasmid were identified. This fact suggests that contact with horses might be another significant source of *R. equi* infection in humans in Cuba (transportation by horse-drawn vehicles is a common practice in rural areas), although of comparatively lesser importance than pigs or pig farm environments.

The *traA* gene, used in the TRAVAP typing scheme as an indicator of “presence of a virulence plasmid” (13), encodes a putative conjugative relaxase that is conserved in the three host-associated virulence plasmid types (11, 12). Ocampo et al. demonstrated that of 89 vapA/B-negative strains, 40 (44.9%) tested positive for the *traA* gene, indicating that they could also contain a plasmid (13). This *traA<sup>+</sup>/vap<sup>+</sup>A<sup>−</sup>B<sup>−</sup> genotype was later shown to correspond to strains carrying the bovine (ruminant)-associated pVAPN (12). In the study by Ocampo-Sosa et al., as many as 26% of the human isolates analyzed carried the bovine-associated *traA<sup>+</sup>/vap<sup>+</sup>A<sup>−</sup>B<sup>−</sup>* (pVAPN) plasmid, suggesting that cattle farm environments are a significant source of human *R. equi* infections. This does not seem to be the case in Cuba, because in the series of 26 isolates analyzed here, only one (3.8%) was positive to the vap<sup>N</sup> marker. Our data are comparable to those of Ribeiro et al. in Brazil, who found that only two out of 74 *R. equi* strains isolated from the lungs of HIV/AIDS patients in the period 1997–2016 carried the vap<sup>N</sup> (pVAPN) plasmid (17).

It must be noted that before the introduction of the *traA* marker in 2006 (13), many of the *traA<sup>+</sup>/vap<sup>+</sup>A<sup>−</sup>B<sup>−</sup>* (pVAPN) strains—mostly bovine and human clinical isolates—were initially considered to be devoid of a virulence plasmid. This means that all the *R. equi* literature prior to the discovery of the *traA* (13) and vapN (12) gene markers, particularly those studies reporting “avirulent/plasmidless” human isolates, must be interpreted with caution. Nevertheless, a significant proportion of *R. equi* human isolates (23 to 43%) actually appear to be devoid of a virulence plasmid, as judged by their negative reaction to the TRAVAP markers (13, 15). This seems to be the case for most of the human strains analyzed in our study, in which the TRAVAP-negative genotype clearly predominated (53.8% of isolates). This high percentage of “avirulent/plasmidless” isolates could be explained by the increased susceptibility of people living with HIV, which may render the virulence plasmid dispensable for *R. equi* to cause an infection. About half of environmental soil isolates of *R. equi* lack a virulence plasmid (13), presumably because it imposes a fitness cost during saprophytic growth in the absence of host selection (2, 8). It is therefore possible to speculate that the *R. equi* strains found in human patients could primarily be non-virulent environmental isolates not directly associated with an animal host. Alternatively, the strains could have lost the plasmid during subculturing in the laboratory. Indeed, spontaneous virulence plasmid curing can be observed during in vitro growth of *R. equi* at 37°C (21, 22). However, it cannot be excluded that some of the 14 TRAVAP-negative isolates might harbor some unknown plasmid encoding novel virulent determinants.

Finally, one isolate was positive to *traA* but negative to each of the plasmid type-specific markers vapA, vapB, and vapN. A similar situation was previously observed in a human isolate in a study performed in the United State of America (15), suggesting that there might be microvariability in some of the virulence plasmids’ PCR target sequences. An alternative and more interesting possibility is that this may reflect the existence of an additional virulence plasmid type(s) yet to be characterized. It is also worth noting that the vap<sup>N</sup> isolate was negative for *traA*, suggesting the existence of microvariability in the *traA* sequence (the *traA* gene is actually a pseudogene in the pVAPN plasmid and is thus theoretically prone to genetic drift) (12). The possibility of TRAVAP gene marker variability may also in part account for the lack of detection of the virulence plasmid in a number of the “avirulent/plasmidless” *R. equi* isolates.

Our study has three limitations: (i) small sample size (*n* = 26), although the isolates were obtained in a period of 7 years and included all cases of *R equi* / HIV coinfection admitted at IPK hospital; (ii) we did not isolate/sequence the virulence plasmids, which would have provided insight into their genetic makeup or the variability underlying the unusual *traA<sup>+</sup>/vap<sup>+</sup>A<sup>−</sup>B<sup>−</sup>* and *traA<sup>+</sup>/vap<sup>+</sup>A<sup>−</sup>B<sup>−</sup>/vap<sup>N</sup>− TRAVAP genotypes; and (iii) a history of contact with farm animals, manure or occupational exposure to farm environments was not available from the clinical records. In any case, this study has value in that it is the first, to our knowledge, in reporting the molecular characterization of *R. equi* isolates in people living with HIV/AIDS in Cuba, and indeed in the Caribbean islands.

In summary, our study provides interesting insight into possible animal sources of *R. equi* infection in AIDS patients from Cuba, of value to public health authorities and, more generally, in the interpretation of the epidemiology of *R. equi* infections in people.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Comité de Ética del Instituto Pedro Kouri. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

YA, EC, and JV-B: conceptualization and supervision. DS-R, YA-S, EI, JV-B, and YA: methodology. AP-H and HP-G: formal analysis. YA, EI, EC, and JV-B: data curation and writing—review and editing. DS-R, YA-S, AP-H, and HP-G: writing—original draft preparation. DS-R and YA-S: visualization. All authors have read and agreed to the published version of the manuscript.

ACKNOWLEDGMENTS

JV-B would like to thank the Horserace Betting Levy Board (UK) for supporting R. equi research in his laboratory (grants prj 764/70 and prj 796).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fvets.2021.628239/full#supplementary-material

REFERENCES

1. Vázquez-Boland JA, Scortti M, Meijer WG. Conservation of Rhodococcus equi (Magnusson 1923) Goodfellow and Alderson 1977 and rejection of Rhodococcus haagii (Morse 1912) Kämpfer et al. Int J Syst Evol Microbiol. (2020) 70:3572–6. doi: 10.1099/ijsem.0.064090

2. Vázquez-Boland JA, Meijer WG. The pathogenic actinobacterium Rhodococcus equi: what’s in a name? Mol Microbiol. (2019) 112:1–15. doi: 10.1111/mmi.14267

3. Takai S, Sawada N, Nakayama Y, Ishizuka S, Nakagawa R, Kawashima G, et al. Reinvestigation of the virulence of Rhodococcus equi isolates from patients with and without AIDS. Lett Appl Microbiol. (2020) 71:679–83. doi: 10.1111/lam.13386

4. Vergidis P, Ariza-Heredia EJ, Nellore A, Kotton CN, Kaul DR, Morris MI, et al. Comparative genomics of Rhodococcus equi: the 85-kilobase plasmid and plasmid-encoded virulence-associated protein traA based on variable proteins. (2014) 172:256–62. doi: 10.1128/JB.00468-08

5. MacArthur I, Anastasi E, Alvarez S, Scortti M, Vázquez-Boland JA. Evolution of the Rhodococcus equi virulence plasmid markers. (2017) 33:870–91. doi: 10.1111/j.1574-6976.2009.00181.x

6. von Bargen K, Haas A. Molecular and infection biology of the Rhodococcus equi horse pathogen. (2007) 190:5797–805. doi: 10.1128/IAI.00468-08

7. Willingham-Lane JM, Berghaus LJ, Giguère S, Hondalus MK. Influenence of vapN and vapA and vapB virulence plasmid type on the replication of Rhodococcus equi in host macrophages. mSphere. (2016) 1:e00186–16. doi: 10.1128/mSphere.00186-16

8. MacArthur I, Anastasi E, Alvarez S, Scortti M, Vázquez-Boland JA. Comparative genomics of Rhodococcus equi virulence plasmids indicates host-driven evolution of the vap Pathogenicity Island. Genome Biol Evol. (2017) 9:1241–7. doi: 10.1093/gbe/evx057

9. Takai S, Hines SA, Sekizaki T, Nicholson VM, Alperin, DA, Oasaki M, et al. DNA sequence and comparison of virulence plasmids from Rhodococcus equi ATCC 33701 and 103. Infect Immun. (2000) 68:6840–7. doi: 10.1128/IAI.68.12.6840-6847.2000

10. Takai S, Tharavichitkul P, Takam P, Khantab T, Tamura M, Tsubaki S, et al. Molecular epidemiology of Rhodococcus equi of intermediate virulence isolated from patients with and without acquired immune deficiency syndrome in Chiang Mai, Thailand. J Infect Dis. (2003) 188:1717–23. doi: 10.1086/379739

11. Letek M, Ocampo-Sosa AA, Sanders M, Fogarty U, Buckley T, Leadon DP, et al. Evolution of the Rhodococcus equi vap pathogenicity island seen through comparison of host-associated vapA and vapB virulence plasmids. J Bacteriol. (2008) 190:5797–805. doi: 10.1128/JB.00468-08

12. Valero-Rello A, Hapeshi A, Anastasi E, Alvarez S, Scortti M, Meijer WG, et al. Inverteron-like linear plasmid mediates intracellular survival and virulence in bovine isolates of Rhodococcus equi. Infect Immun. (2015) 83:2725–37. doi: 10.1128/IAI.00376-15

13. Ocampo-Sosa A, Lewis DA, Navas J, Quigley F, Callejo R, Scortti M, et al. Molecular epidemiology of Rhodococcus equi based on trA, vapA, and vapB virulence plasmid markers. J Infect Dis. (2007) 196:763–9. doi: 10.1086/519688

14. Salazar Rodríguez D, Mígidaia Reyes T, Rodríguez Delgado F, Banderá Tirado F, Reyes Pérez A, Medina Almeneras VZ, et al. First molecular detection of Rhodococcus equi in a HIV/AIDS patient in Cuba. Rev Cubana Med Trop. (2011) 63:253–6.

15. Bryan LK, Alexander ER, Lawhon SD, Cohen ND. Detection of vapN in Rhodococcus equi isolates cultured from humans. PLoS ONE. (2020) 15:e0235719. doi: 10.1371/journal.pone.0235719

16. Ladrón N, Fernández M, Agüero J, González Zorn B, Vázquez-Boland JA, Navas J. Rapid identification of Rhodococcus equi by a PCR assay targeting the choE gene J Clin Microbiol. (2003) 41:3241–5. doi: 10.1128/JCM.41.7.3241-3245.2003

17. Ribeiro MG, Lara GHR, da Silva P, Franco MMJ, de Mattos-Guaraldi AL, de Vargas APC, et al. Novel bovine-associated pVAPN plasmid type in Rhodococcus equi identified from lymph nodes of slaughtered cattle and lungs of people living with HIV/AIDS. Transbound Emerg Dis. (2018) 65:321–6. doi: 10.1111/tbed.12785

18. Ribeiro MG, Takai S, de Vargas AC, Mattos-Guaraldi AL, Ferreira Camello TC, Ohno R, et al. Identification of virulence-associated plasmids in Rhodococcus equi in humans with and without acquired immunodeficiency syndrome in Brazil. Am J Trop Med Hyg. (2011) 85:510–3. doi: 10.4269/ajtmh.2011.10-0695

19. Takai S, Koike K, Obbsushi C, Izumi C, Tsubaki S, Identification of 15- to 17-kilodalton antigens associated with virulent Rhodococcus equi J Clin Microbiol. (1991) 29:439–43. doi: 10.1128/CM.29.3.439-44.3.1991

20. Giguere S, Hondalus MK, Yager JA, Darrah P, Mosser DM, Prescott JF. Role of the 85-kilobase plasmid and plasmid-encoded virulence-associated protein A in intracellular survival and virulence of Rhodococcus equi. Infect Immun. (1999) 67:3548–57. doi: 10.1128/IAI.67.7.3548-3557.1999

21. Takai S, Sugawara YT, Watanabe Y, Sasaki Y, Tsubaki S, Sekizaki T. Effect of growth temperature on maintenance of virulent Rhodococcus equi. Vet Microbiol. (1994) 39:187–92. doi: 10.1016/0378-1135(94)90099-X

22. González-Iglesias P, Scortti M, MacArthur I, Hapeshi A, Rodríguez H, Prescott JF, et al. Mouse lung infection model to assess Rhodococcus equi virulence and vaccine protection. Vet Microbiol. (2014) 172:256–64. doi: 10.1016/j.vetmic.2014.03.026

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.